(Q51893056)

17 April 2018

title

Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. (English)

1 reference

17 April 2018

cost-effectiveness analysis

1 reference

1 reference

1

1 reference

17 April 2018

Richard Zimmerman

2

1 reference

17 April 2018

Mary Patricia Nowalk

4

object named as

Mary Patricia Nowalk

1 reference

Mary Catherine McEllistrem

17 April 2018

6

object named as

M Catherine McEllistrem

1 reference

17 April 2018

Chyongchiou J. Lin

3

object named as

Chyongchiou J Lin

1 reference

17 April 2018

author name string

Feng-Shou Ko

5

1 reference

17 April 2018

Mark S Roberts

7

1 reference

17 April 2018

language of work or name

English

0 references

publication date

29 January 2008

1 reference

17 April 2018

published in

Vaccine

1 reference

17 April 2018

volume

26

1 reference

17 April 2018

issue

11

1 reference

17 April 2018

page(s)

1420-1431

1 reference

17 April 2018

Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Pneumococcal antibody levels one decade after immunization of healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Safety of revaccination with pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

A need to update and revise the pneumococcal vaccine recommendations for adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Decreasing invasive pneumococcal disease in the elderly: a state-level analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

The 23-Valent Pneumococcal Polysaccharide Vaccine. Part II. A Cost-Effectiveness Analysis for Invasive Disease in the Elderly in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Survival after the onset of congestive heart failure in Framingham Heart Study subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Profile for estimating risk of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Pneumococcal Vaccination and Revaccination of Older Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Immunogenicity of pneumococcal revaccination in patients with chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.01.007

1 reference

17 April 2018

1 reference

17 April 2018